ZLNA News

Latest breaking news and updates for ZLNA stock.

Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General Business Update

Oslo, Norway, 20 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces it...

How does Zelluna's performance and outlook compare to other off‑the‑shelf cell‑therapy peers? What updates were provided on the TCR‑NK therapy pipeline and regulatory timelines? How will the Q2 2025 earnings and cash position affect Zelluna's short-term valuation?

Earnings

21 days ago

Zelluna ASA: Invitation to Second Quarter 2025 results webcast presentation

Oslo, Norway, 14 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, invites you to a...

How does the company's valuation multiples (EV/Revenue, EV/EBITDA) compare to peer biotech firms in the cell therapy space? Is there any guidance on upcoming catalysts (e.g., data read‑outs, trial initiations) that could drive stock momentum? What are the key risks highlighted by management that could affect the company's valuation going forward?

Earnings

26 days ago